微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 19.45% | 4.92% | -17.97% | 140/159 | 22.81% | 海创药业 | 99.57% | 行业排名> |
| 2024-06-30 | 23.71% | 41.94% | 5.4% | 134/159 | 33.25% | 海创药业 | 99.52% | 行业排名> |
| 2024-03-31 | 22.5% | 47.46% | 18.12% | 133/159 | 51.56% | 艾力斯 | 96.74% | 行业排名> |
| 2023-12-31 | 19.05% | 24.72% | 2.72% | 141/159 | 51.39% | 首药控股 | 98.96% | 行业排名> |
| 2023-09-30 | 18.54% | 10.54% | 10.98% | 140/159 | 32.56% | 迪哲医药 | 97.73% | 行业排名> |
| 2023-06-30 | 16.71% | -8.71% | 9.51% | 140/159 | 38.45% | 百利天恒 | 97.99% | 行业排名> |
| 2023-03-31 | 15.26% | -28.59% | -0.09% | 137/159 | 52.78% | 百利天恒 | 98.92% | 行业排名> |
| 2022-12-31 | 15.27% | -6.24% | -8.96% | 145/159 | 53.66% | 迈威生物 | 98.93% | 行业排名> |
| 2022-09-30 | 16.77% | -4.6% | -8.34% | 136/159 | 6.2% | 迈威生物 | 99.59% | 行业排名> |
| 2022-06-30 | 18.3% | 1.3% | -14.34% | 141/159 | 21.37% | 迈威生物 | 99.8% | 行业排名> |
| 2022-03-31 | 21.36% | -8.7% | 31.17% | 131/159 | 54.28% | 迈威生物 | 99.46% | 行业排名> |
| 2021-12-31 | 16.29% | -29.5% | -7.37% | 145/159 | 55.1% | 迈威生物 | 99.75% | 行业排名> |
| 2021-09-30 | 17.58% | -20.15% | -2.67% | 128/159 | 46.78% | 迈威生物 | 99.67% | 行业排名> |
| 2021-06-30 | 18.07% | -25.18% | -22.8% | 137/159 | 47.23% | 迈威生物 | 99.44% | 行业排名> |
| 2021-03-31 | 23.4% | -0.18% | 1.29% | 115/159 | 53.99% | 迈威生物 | 98.57% | 行业排名> |
| 2020-12-31 | 23.1% | 15.18% | 4.91% | 133/159 | -145.9% | 首药控股 | 99.93% | 行业排名> |
| 2020-09-30 | 22.02% | 9.43% | -8.81% | 111/159 | 56.36% | 艾力斯 | 99.41% | 行业排名> |
| 2020-06-30 | 24.15% | 19.92% | 3.01% | 118/159 | 54.11% | 艾力斯 | 98.7% | 行业排名> |
| 2020-03-31 | 23.44% | 18.29% | 16.88% | 103/159 | 55.23% | 艾力斯 | 99.4% | 行业排名> |
| 2019-12-31 | 20.06% | -11.12% | -0.33% | 131/159 | -1222.98% | 首药控股 | 99.94% | 行业排名> |
| 2019-09-30 | 20.12% | -15.24% | -0.06% | 103/159 | 55.21% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-06-30 | 20.14% | -10.95% | 1.61% | 110/159 | 55.21% | 微芯生物 | 95.14% | 行业排名> |
| 2019-03-31 | 19.82% | -21.86% | -12.18% | 102/159 | 51.05% | 多瑞医药 | 95.59% | 行业排名> |
| 2018-12-31 | 22.57% | -4.51% | -4.95% | 126/159 | -208.09% | 微芯生物 | 95.81% | 行业排名> |
| 2018-09-30 | 23.74% | 3.23% | 4.99% | 98/159 | 53.97% | 微芯生物 | 96.09% | 行业排名> |
| 2018-06-30 | 22.61% | -8.29% | -10.84% | 102/159 | 53.39% | 微芯生物 | 96.11% | 行业排名> |
| 2018-03-31 | 25.36% | -2.95% | 7.32% | 95/159 | 53.9% | 微芯生物 | 95.5% | 行业排名> |
| 2017-12-31 | 23.63% | -2.34% | 2.76% | 113/159 | 52.32% | 微芯生物 | 96.27% | 行业排名> |
| 2017-09-30 | 23% | -0.19% | -6.73% | 91/159 | 49% | 贝达药业 | 95.47% | 行业排名> |
| 2017-06-30 | 24.66% | 5.26% | -5.65% | 93/159 | 47.74% | 贝达药业 | 95.51% | 行业排名> |
| 2017-03-31 | 26.13% | 15.46% | 7.99% | 74/159 | 46.55% | 贝达药业 | 95.54% | 行业排名> |
| 2016-12-31 | 24.2% | 11.84% | 5.03% | 101/159 | 48.19% | 贝达药业 | 95.74% | 行业排名> |
| 2016-09-30 | 23.04% | 6.87% | -1.64% | 73/159 | 45.76% | 退市金泰 | 96.19% | 行业排名> |
| 2016-06-30 | 23.42% | 7.82% | 3.5% | 81/159 | 45.89% | 贝达药业 | 95.81% | 行业排名> |
| 2016-03-31 | 22.63% | 2.6% | 4.6% | 69/159 | 43.5% | 退市金泰 | 95.93% | 行业排名> |
| 2015-12-31 | 21.64% | 12.22% | 0.37% | 95/159 | 45.97% | 贝达药业 | 95.58% | 行业排名> |
| 2015-09-30 | 21.56% | 17.86% | -0.77% | 69/159 | 44.69% | 贝达药业 | 95.89% | 行业排名> |
| 2015-06-30 | 21.73% | 24.27% | -1.51% | 71/159 | 45% | 微芯生物 | 97.46% | 行业排名> |
| 2015-03-31 | 22.06% | 2% | 14.4% | 65/159 | 43.46% | 贝达药业 | 97.01% | 行业排名> |